CR10831A - INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA - Google Patents
INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASAInfo
- Publication number
- CR10831A CR10831A CR10831A CR10831A CR10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ketona
- carboxilasa
- espiro
- acetil
- coa
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86177906P | 2006-11-29 | 2006-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10831A true CR10831A (es) | 2009-06-18 |
Family
ID=39126209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10831A CR10831A (es) | 2006-11-29 | 2009-05-28 | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090270435A1 (es) |
| EP (1) | EP2097420B1 (es) |
| JP (1) | JP2010511035A (es) |
| KR (1) | KR20090083956A (es) |
| CN (1) | CN101541809A (es) |
| AP (1) | AP2009004880A0 (es) |
| AT (1) | ATE552262T1 (es) |
| AU (1) | AU2007326950B2 (es) |
| BR (1) | BRPI0721053A2 (es) |
| CA (1) | CA2670422C (es) |
| CO (1) | CO6180424A2 (es) |
| CR (1) | CR10831A (es) |
| EA (1) | EA200900613A1 (es) |
| EC (1) | ECSP099371A (es) |
| IL (1) | IL198779A0 (es) |
| MA (1) | MA30932B1 (es) |
| MX (1) | MX2009005604A (es) |
| NO (1) | NO20091889L (es) |
| RS (1) | RS20090249A (es) |
| SV (1) | SV2009003281A (es) |
| TN (1) | TN2009000204A1 (es) |
| WO (1) | WO2008065508A1 (es) |
| ZA (1) | ZA200903268B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20081559A1 (es) * | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008088692A2 (en) * | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| CN100550853C (zh) * | 2007-01-25 | 2009-10-14 | 华为技术有限公司 | 一种基于输出队列的流控实现方法及装置 |
| DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| EP2297164A1 (en) * | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2307422B1 (en) | 2008-07-04 | 2014-03-26 | Msd K.K. | Novel spirochromanone carboxylic acids |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| EP2184276A1 (en) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
| CA2778316A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| UA102336C2 (uk) * | 2009-11-10 | 2013-06-25 | Пфайзер Інк. | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ |
| ES2557895T3 (es) | 2010-03-19 | 2016-01-29 | Pfizer Inc | Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| DK2621493T3 (en) | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| KR101923367B1 (ko) | 2011-02-02 | 2018-12-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드 |
| WO2012112743A1 (en) * | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| EA022375B1 (ru) | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| WO2013007603A1 (de) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Verfahren zur herstellung von 2-amino-5-cyano-n,3-dimethylbenzamid |
| JP2014520879A (ja) | 2011-07-15 | 2014-08-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| ES2561105T3 (es) | 2011-08-18 | 2016-02-24 | Nippon Shinyaku Co., Ltd. | Derivado heterocíclico como inhibidor de prostaglandina E sintasa microsómica (mPGES) |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| AU2012335220B2 (en) | 2011-11-11 | 2017-06-01 | Pfizer Inc. | 2-thiopyrimidinones |
| AU2013245353A1 (en) | 2012-04-06 | 2014-09-25 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| ES2665153T3 (es) | 2013-10-09 | 2018-04-24 | Pfizer Inc. | Antagonistas del receptor EP3 de prostaglandina |
| CU24395B1 (es) | 2014-03-17 | 2019-04-04 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| PL3536685T3 (pl) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| JP6111002B1 (ja) | 2014-04-10 | 2017-04-05 | ファイザー・インク | ２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| SG11201708407TA (en) | 2015-05-05 | 2017-11-29 | Pfizer | 2-thiopyrimidinones |
| WO2016193844A1 (en) | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| DK3310784T3 (da) | 2015-06-17 | 2020-11-09 | Pfizer | Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20180230127A1 (en) | 2015-08-13 | 2018-08-16 | Pfizer Inc. | Bicyclic-Fused Heteroaryl Or Aryl Compounds |
| HRP20210472T1 (hr) | 2015-08-27 | 2021-05-14 | Pfizer Inc. | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
| TN2018000198A1 (en) | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| CN108658938B (zh) * | 2018-06-15 | 2021-03-23 | 上海现代制药股份有限公司 | 一种甲磺酸达比加群酯工艺杂质的合成方法 |
| CN108774242B (zh) * | 2018-08-22 | 2020-10-27 | 牡丹江医学院 | 一种防治冠心病的药物及其制备方法 |
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| CN109400618B (zh) * | 2018-11-09 | 2021-08-10 | 中国药科大学 | 一种色满衍生物及其制备方法和应用 |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| CN109809992A (zh) * | 2019-02-16 | 2019-05-28 | 安徽华胜医药科技有限公司 | 一种2-（2-氟-3-甲氧基苯基）-2-羟基乙酸乙酯的合成方法 |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110128347A (zh) * | 2019-06-17 | 2019-08-16 | 韶远科技（上海)有限公司 | 一种1-甲基-1h-吲唑-6-甲酸的合成方法 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114437096B (zh) * | 2020-11-06 | 2025-09-12 | 上海医药集团股份有限公司 | 一种螺杂环类化合物、其制备方法及应用 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| TW202530207A (zh) * | 2023-08-16 | 2025-08-01 | 智擎生技製藥股份有限公司 | Ｍｔａ協同性的ｐｒｍｔ５抑制劑 |
| WO2025133948A1 (en) * | 2023-12-21 | 2025-06-26 | Pfizer Inc. | Acetyl coa-carboxylase (acc) inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| AU705661B2 (en) * | 1995-06-06 | 1999-05-27 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| WO2002020509A2 (de) * | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Arzneimittel gegen virale erkrankungen |
| JPWO2004092179A1 (ja) * | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) * | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| EP1802623A1 (en) * | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| JP2008540395A (ja) * | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
-
2007
- 2007-11-16 WO PCT/IB2007/003639 patent/WO2008065508A1/en not_active Ceased
- 2007-11-16 BR BRPI0721053-1A patent/BRPI0721053A2/pt not_active IP Right Cessation
- 2007-11-16 EP EP07825738A patent/EP2097420B1/en active Active
- 2007-11-16 RS RSP-2009/0249A patent/RS20090249A/sr unknown
- 2007-11-16 AU AU2007326950A patent/AU2007326950B2/en not_active Expired - Fee Related
- 2007-11-16 CA CA2670422A patent/CA2670422C/en not_active Expired - Fee Related
- 2007-11-16 AP AP2009004880A patent/AP2009004880A0/xx unknown
- 2007-11-16 AT AT07825738T patent/ATE552262T1/de active
- 2007-11-16 KR KR1020097013481A patent/KR20090083956A/ko not_active Ceased
- 2007-11-16 JP JP2009538803A patent/JP2010511035A/ja active Pending
- 2007-11-16 MX MX2009005604A patent/MX2009005604A/es not_active Application Discontinuation
- 2007-11-16 EA EA200900613A patent/EA200900613A1/ru unknown
- 2007-11-16 US US12/514,596 patent/US20090270435A1/en not_active Abandoned
- 2007-11-16 CN CNA2007800442537A patent/CN101541809A/zh active Pending
-
2009
- 2009-05-12 ZA ZA200903268A patent/ZA200903268B/xx unknown
- 2009-05-14 NO NO20091889A patent/NO20091889L/no not_active Application Discontinuation
- 2009-05-14 IL IL198779A patent/IL198779A0/en unknown
- 2009-05-22 TN TNP2009000204A patent/TN2009000204A1/fr unknown
- 2009-05-28 CR CR10831A patent/CR10831A/es not_active Application Discontinuation
- 2009-05-28 CO CO09054954A patent/CO6180424A2/es not_active Application Discontinuation
- 2009-05-29 SV SV2009003281A patent/SV2009003281A/es not_active Application Discontinuation
- 2009-05-29 MA MA31936A patent/MA30932B1/fr unknown
- 2009-05-29 EC EC2009009371A patent/ECSP099371A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20090270435A1 (en) | 2009-10-29 |
| CO6180424A2 (es) | 2010-07-19 |
| EP2097420A1 (en) | 2009-09-09 |
| EA200900613A1 (ru) | 2009-10-30 |
| TN2009000204A1 (fr) | 2010-10-18 |
| AU2007326950B2 (en) | 2010-10-14 |
| NO20091889L (no) | 2009-06-17 |
| MA30932B1 (fr) | 2009-11-02 |
| EP2097420B1 (en) | 2012-04-04 |
| CA2670422C (en) | 2011-09-06 |
| CN101541809A (zh) | 2009-09-23 |
| SV2009003281A (es) | 2010-08-17 |
| WO2008065508A1 (en) | 2008-06-05 |
| RS20090249A (sr) | 2010-06-30 |
| MX2009005604A (es) | 2009-06-08 |
| JP2010511035A (ja) | 2010-04-08 |
| IL198779A0 (en) | 2010-02-17 |
| ATE552262T1 (de) | 2012-04-15 |
| BRPI0721053A2 (pt) | 2014-07-29 |
| ZA200903268B (en) | 2010-07-28 |
| AP2009004880A0 (en) | 2009-06-30 |
| KR20090083956A (ko) | 2009-08-04 |
| CA2670422A1 (en) | 2008-06-05 |
| AU2007326950A1 (en) | 2008-06-05 |
| ECSP099371A (es) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0719204A2 (pt) | Inibidores de hdac | |
| EP2051707A4 (en) | Plasma kallikrein INHIBITORS | |
| CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
| DE602006004717D1 (de) | Kapselperforationsmodul | |
| DE602007002544D1 (de) | Nuancierungsmittel | |
| DE602007008423D1 (de) | Flüssigkeitshärtung | |
| AT504580A3 (de) | Scan-einrichtung | |
| DE602007003893D1 (de) | Kippambossanordnung | |
| DE602007006947D1 (de) | Pyridopyrimidinonderivate | |
| DE602007000258D1 (de) | Kassetteneinspannmechanismus | |
| DE602007001280D1 (de) | Getränkeextraktor | |
| DE602006020192D1 (de) | Riemenscheibenanorndung | |
| DE602007001098D1 (de) | Spindelmäheinheit | |
| DE502007001629D1 (de) | Rfahren | |
| ATE546437T1 (de) | Aminomethyl-4-imidazole | |
| DE502007000218D1 (de) | nsetzungen | |
| DE602007000501D1 (de) | Breitbandrichtkoppler | |
| DE502007002453D1 (de) | Kunstoffverdichtergehäuse | |
| DE602007007460D1 (de) | Sehkrafttestsystem | |
| DE602007004080D1 (de) | Tintenstrahlaufnehmer | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
| DE602007000333D1 (de) | Napfbefestigungsvorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |